Successful Approval of manufacturing and laboratory facilities by Saudi Food and Drug Authority

New site approval! We are happy to announce that our manufacturing and laboratory facilities for oral solids at AET Laboratories in Hyderabad (India) have been successfully registered by the Saudi Food and Drug Authority.

The registration is a great door opener for the full GCC region. It is an important addition to our existing European and international certifications (like the US FDA approval) and follows Tiefenbacher Group´s strategy to make our high-quality pharmaceuticals better available worldwide!

About Tiefenbacher Group– Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines  around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our goal is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.  

For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email atinfo@tiefenbacher.com 


TIEFENBACHER GROUP IS COMMITTED TO BECOMING CLIMATE NEUTRAL

We are pleased to share that TIEFENBACHER GROUP is committed to becoming climate neutral by the end of 2025*. As a value-driven healthcare company, dedicated to improving the life of patients worldwide, we recognize the importance of taking action to address the urgent climate crisis we face today. To achieve this goal, we are implementing a comprehensive sustainability strategy that includes the following measures, among others:

As our biggest driver of the carbon footprint is energy consumption, large-scale solar panels will be installed on our manufacturing facilities in Cyprus and India. Any electricity that cannot be produced in-house and must be purchased will be purely green electricity. In addition, we are implementing energy saving and efficiency measures – especially at our production sites. Furthermore, all company vehicles will be exclusively electric in the future. With these measures, we will already achieve a great interim goal: reducing our emissions by 80% by January 2024.

We believe that this is not only the right thing to do for the planet but also the right thing to do for our business. Being commercially successful and operating responsibly by becoming climate neutral is how we generate sustainable returns. We look forward to sharing more updates on our progress towards this important goal in the coming months and years.

*Scope 1 and 2 according to GHG as well as business travel and employee commuting

About Tiefenbacher Group– Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines  around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our goal is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.  

For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email atinfo@tiefenbacher.com 


Featured Video Play Icon

RENOVATING HEADQUARTERS IN HAMBURG

Did you know that Tiefenbacher Group is currently renovating its headquarters in Hamburg, Germany? We are excited to share the first results of the restructuring and are pleased to bring the first changes to life.

The newly designed building will be a modern and innovative workspace that reflects our culture of entrepreneurship, professional excellence, and openness. The open-floor concept promotes creativity, collaboration, and teamwork among our employees. We believe that the new space, right on the banks of the river Elbe, provides a great working environment that supports the growth and wellbeing of our employees at the same time.

Watch our short video to see the first changes. We´ll keep you posted on the progress and look forward to welcoming you to our new office space soon!

About Tiefenbacher Group– Pioneering Healthcare since 1963 
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines  around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our goal is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.  

For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email atinfo@tiefenbacher.com 


Featured Video Play Icon

TIEFENBACHER GROUP AT DCAT 2023 – THANKS FOR MEETING US IN NEW YORK CITY!

DCAT week – one of the world´s most important pharma events – has just come to an end. It was four very successful and inspiring days for TIEFENBACHER GROUP in New York City. What a pleasure to present our latest product portfolio and innovations and to connect with existing and potential new partners. Check out our short video to get some impressions!

About Tiefenbacher Group– Pioneering Healthcare since 1963 
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines  around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our goal is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.  

For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email atinfo@tiefenbacher.com 


Featured Video Play Icon

TIEFENBACHER GROUP wishes a happy and healthy Chinese New Year 2023!

We at TIEFENBACHER GROUP appreciate the diversity of our colleagues very much and are happy to celebrate their local traditions together. In the culture of our Chinese partners and colleagues, a certain animal of the Chinese zodiac is assigned to each year. This year is the year of the rabbit. Watch our colleague Danna from China sharing short Lunar New Year greetings in her local language!

About Tiefenbacher Group– Pioneering Healthcare since 1963 
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines  around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our goal is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.  

For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email atinfo@tiefenbacher.com 


Featured Video Play Icon

TIEFENBACHER GROUP WISHES A HEALTHY NEW YEAR 2023

From all over the world, we wish you a happy and healthy New Year 2023!

In order to serve more than 80 national markets in the best possible way for our partners, we are particularly proud to have so many different nationalities and cultures at TIEFENBACHER GROUP. Watch our colleagues from our various locations sharing short New Year’s greetings in their respective national languages with you.

For information about our product portfolio and innovative health care solutions please contact TIEFENBACHER GROUP: info@aet.eu or visit us on: www.tiefenbachergroup.com

About Tiefenbacher Group– Pioneering Healthcare since 1963 
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines  around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our goal is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.  

For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email atinfo@tiefenbacher.com 


Featured Video Play Icon

Thanks for visiting us at CPhI 2022 in Frankfurt!

CPhI 2022, the world`s leading pharma event, has just come to an end. It was wonderful to meet our valued customers and partners in person again. Our experts enjoyed three very successful days full of exciting meetings and inspiring discussions. It was a great pleasure to present TIEFENBACHER GROUP´s latest ideas to make pharmaceuticals more affordable, more available, and better than before.  

Thanks a lot for visiting us at our new booth representing TIEFENBACHER GROUP as a global health pioneer. We are already looking forward to seeing you next year in Barcelona at CPhI 2023! 

About Tiefenbacher Group– Pioneering Healthcare since 1963 
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines  around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our goal is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.  

For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email atinfo@tiefenbacher.com 


Featured Video Play Icon

TIEFENBACHER GROUP opens new manufacturing site in Cyprus

Did you know that TIEFENBACHER GROUP heavily invests in its in-house production capacities? We are excited to announce that our new manufacturing site in Cyprus was ceremoniously opened in mid-October. The “Delorbis” plant is one of the most modern pharmaceutical production site in the European Union. Its facilities are equipped with state-of-the art technologies for the manufacturing of oral dosage forms. This investment follows TIEFENBACHER GROUP´s strategy to strengthen its position as a global, fully integrated pharmaceutical company.

Check out our short video and get an impression of the festive inauguration of the new plant!

For further information about our portfolio and innovative health care solutions for a better tomorrow please contact TIEFENBACHER GROUP: info@aet.eu or visit us on: www.tiefenbachergroup.com

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963

TIEFENBACHER GROUP is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From initial idea to market access of high-quality pharmaceuticals around the world: We distribute APIs and develop, manufacture, and register finished dosage forms (FDF) as well as medical devices. Our purpose is to improve patients´ lives by creating pharmaceuticals more affordable, more available, and better than before.


TIEFENBACHER GROUP and OnDosis launch the innovative healthcare brand OYSTA®

TIEFENBACHER GROUP and OnDosis are thrilled to announce the launch of OYSTA®. The new healthcare brand represents the cooperation initiated in September 2020, including the co-development portfolio of innovative products in five indications. OYSTA® aims to revolutionize the way how patients take their medicines by combining pharmaceuticals with e-health technology to enable intuitive, precise, and flexible dosing.

TIEFENBACHER GROUP and OnDosis today announced the launch of the OYSTA® brand. OYSTA® represents the extensive co-development portfolio of drug/device combinations that was initiated in September 2020 and covers several indications such as ADHD, Parkinson´s disease, transplantation, and pain medicines as well as rare pulmonary diseases. The first product, combining a stimulant with the proprietary dosage manager for patients with ADHD, is already planned for launch in the US in 2024. Other indications will stand in line as next wave developments.

OYSTA® captures the essence of the value proposition of the products under development: a safe “shell” (proprietary dosage manager) to protect medicines formulated as “pearls” (pellets or granules) to allow for intuitive, flexible, and precise dosing.

Through the OYSTA® collaboration, OnDosis will benefit from a partner with leading competence in pharmaceutical development, supply chain, and B2B commercialization, whilst TIEFENBACHER GROUP gets access to an innovative product concept with game-changing potential in the new era of individualization of treatments and digitalization in healthcare.

“OYSTA® allows us to clearly position the products we are co-developing in conversation with commercialization partners as well as with health care professionals and end users. It is ultimately a sign that our common efforts to bring innovation to patients is getting closer to market” says Kristian Ruepp, Managing Director at TIEFENBACHER GROUP.

“OYSTA® perfectly captures the essence of what we want to achieve together in this exciting collaboration: individualized dosing of solid oral medicines formulated as “pearls” and protected within a device “shell” which gives reassurance to patients, caregivers, and healthcare professionals.  Under one name, we are co-developing a portfolio of innovative products as one team, with the ambition to revolutionize how patients take their medicines. That revolution is now accelerating” says Martin Olovsson, CEO at OnDosis.

TIEFENBACHER GROUP and OnDosis will first present the OYSTA® brand in public at CPhI 2022 in Frankfurt (Nov 1-3). To schedule a meeting please contact TIEFENBACHER GROUP via info@aet.eu.

About TIEFENBACHER GROUP

100% family owned since 1963 TIEFENBACHER GROUP is a global health care company providing innovative and best-in-class solutions along the entire pharmaceutical value chain. That includes the distribution of API ́s and the development, manufacturing, and registration of finished dosage forms. The world ́s most trusted health care brands count on TIEFENBACHER’s pioneer spirit as well as its pharmaceutical excellence. Leveraging its global presence including own laboratories and manufacturing sites, TIEFENBACHER is driven to make pharmaceuticals more affordable, more available, and better than before. There is one purpose driving TIEFENBACHER’s about 800 employees day by day: improving the life of millions of patients worldwide. www.tiefenbachergroup.com

About OnDosis

A Swedish Life science company that will revolutionize the way patients take their medicines. The idea is to deliver the perfect dosage — individualized, intuitive, and intelligent — in a form that is easier to consume. OnDosis has developed a proprietary technology platform that centers around a connected handheld device that delivers customized and easily adjusted doses of oral medicines and enables integration of digital technologies. By combining traditional drug-based treatments with digital therapeutics, OnDosis strives to fulfill its purpose: to ensure that patients get exactly the medicine they need, so they can live the lives they deserve. www.ondosis.com

For any request regarding a collaboration in one of the five indications mentioned above, please contact TIEFENBACHER GROUP. For interest in any other indication or solely the device please contact OnDosis:

Dr. Kristian Ruepp
Joint Managing Director, TIEFENBACHER GROUP

Tel: +49 40 – 44 18 09-0; info@aet.eu

Martin Olovsson
CEO, OnDosis

Tel: +46 76 772 85 01; m.olovsson@ondosis.com

OYSTA® is a registered trademark jointly owned by TIEFENBACHER GROUP and OnDosis. The OYSTA® products are co-developed based in the proprietary dosage manager device platform developed by OnDosis.


Meet TIEFENBACHER GROUP at CPhI in Frankfurt from 1-3 Nov and discover our latest ideas to make pharmaceuticals more affordable, more available, and better than before!

We are very excited to meet our valued customers and partners once again on CPhI 2022, the world´s leading pharma industry event! 

Explore our new booth representing Tiefenbacher Group as a global health pioneer and discover our latest product portfolio and innovations in the field of raw materials, finished dosage forms, and medical devices! Get in touch with our experts to discuss new business opportunities and ideas for improving the life of millions of patients worldwide! 

CPhI 2022 will take place on November 1-3 at Messe Frankfurt, Germany. We’ll be happy to meet you at our stand 80B70 at any time during the event. The arrangement of prescheduled meetings is highly appreciated. Please contact our team to request a meeting or send a meeting request to cphi@aet.eu. 

TIEFENBACHER GROUP – pioneering healthcare since 1963. Please visit us on www.tiefenbachergroup.com